Despite the recent improvement in the outcome of patients with MCL, there is still an unmet need especially after failure of BTK inhibitors, which will ultimately concern most patients, and those with specific molecular characteristics such as TP53 mutation or high MIPI score combined with a high Ki67 (prognostic marker) index. This evidence concerns the gene BTK and mantle cell lymphoma.